Introduction: Local recurrence of conjunctival melanoma (CM) is common after excision. Local radiotherapy is an effective adjuvant treatment option, and brachytherapy with ruthenium-106 (106Ru) is one such option. Thus, herein, we aimed to describe our experience with and the clinical results of post-excision adjuvant 106Ru plaque brachytherapy in patients with CM. Methods: Nineteen patients (8 men and 11 women) received adjuvant brachytherapy with a 106Ru plaque after tumor excision. The mean adjuvant dose administered was 109 Gy (range, 80–134 Gy), and a depth of only 2.2 mm was targeted because the tumor had been excised. A full ophthalmological examination including visual acuity testing, slit-lamp examination, and indirect ophthalmoscopy was performed before therapy and at every postoperative follow-up. The mean follow-up period was 62 months (range, 2–144 months). Results: Three patients developed a recurrence in a nontreated area, at either the conjunctiva bulbi or the conjunctiva tarsi. None of the patients developed a recurrence in the treated area. The local control rate was 84% (16/19). Conclusion:106Ru plaque brachytherapy is an effective adjuvant treatment to minimize the risk of local recurrence after excision of a CM. Patients have to be followed up regularly and carefully for the early detection of recurrence.

1.
Seregard
S
,
Kock
E
.
Conjunctival malignant melanoma in Sweden 1969−91
.
Acta Ophthalmol
.
1992
;
70
(
3
):
289
96
.
2.
Larsen
AC
.
Conjunctival malignant melanoma in Denmark. Epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile
.
Acta Ophthalmol
.
2016
;
94
(
8
):
842
.
3.
Triay
E
,
Bergman
L
,
Nilsson
B
,
All-Ericsson
C
,
Seregard
S
.
Time trends in the incidence of conjunctival melanoma in Sweden
.
Br J Ophthalmol
.
2009
;
93
(
11
):
1524
8
.
4.
Shields
CL
,
Fasiuddin
AF
,
Mashayekhi
A
,
Shields
JA
.
Conjunctival Nevi: clinical features and natural course in 410 consecutive patients
.
Arch Ophthalmol
.
2004
;
122
(
2
):
167
75
.
5.
Shields
CL
,
Markowitz
JS
,
Belinsky
I
,
Schwartzstein
H
,
George
NS
,
Lally
SE
, et al
.
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases
.
Ophthalmology
.
2011
;
118
(
2
):
389
95.e952
.
6.
Damato
B
,
Coupland
SE
.
Management of conjunctival melanoma
.
Expert Rev Anticancer Ther
.
2009
;
9
(
9
):
1227
39
.
7.
Larsen
AC
,
Dahmcke
CM
,
Dahl
C
,
Siersma
VD
,
Toft
PB
,
Coupland
SE
, et al
.
A retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with Braf mutations
.
JAMA Ophthalmol
.
2015
;
133
(
11
):
1295
303
.
8.
Buckman
G
,
Jakobiec
FA
,
Folberg
R
,
McNally
LM
.
Melanocytic nevi of the palpebral conjunctiva: an extremely rare location usually signifying melanoma
.
Ophthalmology
.
1988
;
95
(
8
):
1053
7
.
9.
Coupland
SE
,
Barnhill
R
,
Conway
RM
, et al
.
No title. Conjunctival melanoma
. In:
Amin
MB
,
Edge
S
,
Greene
F
, et al
, editors.
Cancer staging manual
. 8th ed.
New York, NY
:
Springer
;
2017
. p.
803
11
.
10.
Shields
CL
,
Shields
JA
,
Gündüz
K
,
Cater
J
,
Mercado
GV
,
Gross
N
, et al
.
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients
.
Arch Ophthalmol
.
2000
;
118
(
11
):
1497
507
.
11.
Shields
CL
,
Shields
JA
,
Armstrong
T
.
Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy
.
Am J Ophthalmol
.
2001
;
132
(
4
):
576
8
.
12.
Pk
L
.
Beta irradiation of conjunctival melanomas
. In:
Trans ophthalmol soc UK
;
1977
.
13.
Lommatzsch
PK
,
Werschnik
C
.
Das maligne Melanom der Bindehaut - Klinische übersicht mit empfehlungen zur diagnose, therapie und nachsorge
.
Klin Monbl Augenheilkd
.
2002
;
219
(
10
):
710
21
.
14.
Missotten
GS
,
Keijser
S
,
De Keizer
RJW
,
De Wolff-Rouendaal
D
.
Conjunctival melanoma in The Netherlands: a nationwide study
.
Invest Ophthalmol Vis Sci
.
2005
;
46
(
1
):
75
82
.
15.
Krause
L
,
Mladenova
A
,
Bechrakis
NE
,
Kreusel
KM
,
Plath
T
,
Moser
L
, et al
.
[Treatment modalities for conjunctival melanoma]
.
Klin Monbl Augenheilkd
.
2009
;
226
(
12
):
1012
6
.
16.
Krause
L
,
Ritter
C
,
Wachtlin
J
,
Kreusel
KM
,
Höcht
S
,
Foerster
MH
, et al
.
Rezidivhäufigkeit nach exzision von bindehautmelanomen und adjuvanter strontium-90-kontaktbestrahlung
.
Klin Monbl Augenheilkd
.
2008
;
225
(
07
):
649
52
.
17.
Shields
CL
,
Kaliki
S
,
Al-Dahmash
SA
,
Lally
SE
,
Shields
JA
.
American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes
.
Ophthal Plast Reconstr Surg
.
2012
;
28
(
5
):
313
23
.
18.
Westekemper
H
,
Meller
D
,
Darawsha
R
,
Scholz
SL
,
Flühs
D
,
Steuhl
KP
, et al
.
Operative Therapie und Bestrahlung konjunktivaler Melanome
.
Ophthalmologe
.
2015
;
112
(
11
):
899
906
.
19.
Cohen
VML
,
Papastefanou
VP
,
Liu
S
,
Stoker
I
,
Hungerford
JL
.
The use of strontium-90 beta radiotherapy as adjuvant treatment for conjunctival melanoma
.
J Oncol
.
2013
;
2013
:
349162
.
20.
Lederman
M
,
Jones
CH
.
Beta irradiation of the conjunctival sac: description of a new applicator
.
Br J Radiol
.
1966
;
39
(
467
):
867
9
.
21.
Rasmussen
KE
.
[Therapy of superficial eye diseases with the strontium 90 beta-ray applicator]
.
Nord Med
.
1969
;
81
(
11
):
333
7
.
22.
Paridaens
ADA
,
Minassian
DC
,
McCartney
ACE
,
Hungerford
JL
.
Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases
.
Br J Ophthalmol
.
1994
;
78
(
4
):
252
9
.
23.
Tuomaala
S
,
Eskelin
S
,
Tarkkanen
A
,
Kivelä
T
.
Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites
.
Invest Ophthalmol Vis Sci
.
2002
;
43
(
11
):
3399
408
.
24.
Jain
P
,
Finger
PT
,
Fili
M
,
Damato
B
,
Coupland
SE
,
Heimann
H
, et al
.
Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study
.
Br J Ophthalmol
.
2021
;
105
(
10
):
1358
64
.
25.
Brouwer
NJ
,
Marinkovic
M
,
Peters
FP
,
Hulshof
MCCM
,
Pieters
BR
,
de Keizer
RJW
, et al
.
Management of conjunctival melanoma with local excision and adjuvant brachytherapy
.
Eye
.
2021
;
35
(
2
):
490
8
.
26.
Damato
B
,
Coupland
SE
.
An audit of conjunctival melanoma treatment in Liverpool
.
Eye
.
2009
;
23
(
4
):
801
9
.
27.
Jakobiec
FA
,
Brownstein
S
,
Albert
W
,
Schwarz
F
,
Anderson
R
.
The role of cryotherapy in the management of conjunctival melanoma
.
Ophthalmology
.
1982
;
89
(
5
):
502
15
.
28.
Demirci
H
,
Mccormick
S
,
Finger
P
.
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations
.
Arch Ophthalmol
.
2000
;
118
(
7
):
885
91
.
29.
Kurli
M
,
Finger
PT
.
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience
.
Graefe’s Arch Clin Exp Ophthalmol
.
2005
;
243
(
11
):
1108
14
.
30.
Westekemper
H
,
Freistuehler
M
,
Anastassiou
G
,
Nareyeck
G
,
Bornfeld
N
,
Steuhl
KP
, et al
.
Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations
.
Br J Ophthalmol
.
2012
;
96
(
4
):
591
6
.
31.
Khong
JJ
,
Muecke
J
.
Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia
.
Br J Ophthalmol
.
2006
;
90
(
7
):
819
22
.
You do not currently have access to this content.